Long-term risk of bleeding events in patients taking antithrombotic agents for cerebrovascular or cardiovascular disease

Abstract

Background:

Antithrombotic agents are essential for preventing cerebrovascular and cardiovascular diseases; however, bleeding complications remain a major concern, particularly among elderly patients and those receiving combination therapy.

Aims:

We designed the Bleeding with Antithrombotic Therapy 2 (BAT2) Study, a prospective multicenter registry involving hospitals from a clinical research network in Japan, to clarify the risk of bleeding events in patients taking antithrombotic agents for cerebrovascular and cardiovascular diseases in recent clinical settings.

Methods:

This prospective, multicenter, observational study followed bleeding and ischemic events for up to 2 years in patients with cerebrovascular and cardiovascular diseases. The primary outcome was major bleeding, and secondary outcomes included intracranial hemorrhage (ICH).

Results:

The 5250 patients enrolled comprised 3134 (70 ± 11 years; male, 66.6%; HASBLED ⩾ 3, 32.8%) treated with single antiplatelet therapy (SAPT), 551 (71 ± 11 years; 25.8%; 40.8%, respectively) with dual antiplatelet therapy (DAPT), 870 (75 ± 10 years; 37.1%; 39.8%, respectively) with direct oral anticoagulant (DOAC) alone, 433 (72 ± 12 years; 34.2%; 41.4%, respectively) with warfarin alone, 143 (76 ± 8 years; 16.8%; 42.7%, respectively) with DOAC plus antiplatelet agents (AP), and 119 (73 ± 12 years; 18.5%; 47.5%, respectively) with warfarin plus AP. During follow-up (median, 1.98 years), 93 patients experienced major bleeding, and 55 developed ICH. Compared with the SAPT group (37 events, 0.63%/year), the DOAC (18 events, 1.12%/year; adjusted hazard ratio (aHR) = 1.94, 95% confidence interval (CI) = 1.09–3.46), warfarin (16 events, 2.02%/year; 3.44, 1.90–6.23), and DOAC plus AP groups (six events, 2.24%/year; 3.07, 1.28–7.35) exhibited significantly higher risks of major bleeding after multivariable adjustment. DAPT (aHR 2.47, 95% CI = 1.11–5.48), warfarin (5.38, 2.65–10.92), and DOAC plus AP (3.86, 1.30–11.47) had significantly higher risks of ICH than SAPT. The DAPT (2.28, 95% CI = 1.65–3.14), DOAC plus AP (1.96, 1.08–3.56), and warfarin plus AP (2.83, 1.62–4.92) groups showed significantly higher risks of ischemic events than the SAPT group.

Conclusion:

Oral anticoagulant alone and DOAC with antiplatelet therapy were associated with higher risks of major bleeding events than SAPT in long-term follow-up for patients with stroke and cardiovascular disease.

Graphical abstract

Keywords

BAT2 stroke cardiovascular disease bleeding events antithrombotic agent

Get full access to this article

View all access options for this article.

References

Wong

Wang

Leng

, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013; 128: 1656–1666.

Ruff

Giugliano

Braunwald

, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.

Toyoda

Yasaka

Iwade

, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 2008; 39: 1740–1745.

Toyoda

Uchiyama

Yamaguchi

, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 2019; 18: 539–548.

Wang

Zhao

, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.

Kitagawa

Yamamoto

Arima

, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 2019; 76: 1309–1318.

Takagi

Tanaka

Miwa

, et al. The bleeding with antithrombotic therapy study 2: rationale, design, and baseline characteristics of the participants. Eur Stroke J 2020; 5: 423–431.

Tanaka

Miwa

Koga

, et al. Cerebral small vessel disease burden for bleeding risk during antithrombotic therapy: bleeding with antithrombotic therapy 2 study. Ann Neurol 2024; 95: 774–787.

Toyoda

Yamamoto

Koga

Network for Clinical Stroke Trials (NeCST) for the next stroke researchers in Japan. Stroke 2016; 47: 304–305.

10.

Schulman

Kearon

; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.

11.

Miwa

Tanaka

Koga

, et al. Prediction model to optimize long-term antithrombotic therapy using covert vascular brain injury and clinical features. Stroke 2025; 56: 2605–2616.

12.

Ntaios

Papavasileiou

Diener

Makaritsis

Michel

Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017; 12: 589–596.

13.

Rost

Giugliano

Ruff

, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke 2016; 47: 2075–2082.

14.

Sardar

Chatterjee

, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS ONE 2013; 8: e77694.

15.

Lee

Chan

, et al. Oral anticoagulants and antiplatelet agents in patients with atrial fibrillation and concomitant critical limb ischemia: a nationwide cohort study. Can J Cardiol 2021; 37: 113–121.

16.

Coyle

Lynch

Higgins

, et al. Risk of intracranial hemorrhage associated with direct oral anticoagulation vs antiplatelet therapy: a systematic review and meta-analysis. JAMA Netw Open 2024; 7: e2449017.

17.

Bhatt

Fox

Hacke

, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.

18.

Diener

Bogousslavsky

Brass

, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–337.

19.

Trifan

Gorelick

Testai

FD.

Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials. Circulation 2021; 143: 2441–2453.

20.

Benavente

Hart

McClure

, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817–825.

21.

Xie

Zheng

Zhong

, et al. Long-term antiplatelet mono- and dual therapies after ischemic stroke or transient ischemic attack: network meta-analysis. J Am Heart Assoc 2015; 4: e002259.

22.

Pugliese

Arasaratnam

Moellenberg

, et al. Short- vs. long-term dual antiplatelet therapy in secondary prevention for ischaemic stroke: a network metanalysis. Eur Heart J Qual Care Clin Outcomes 2019; 5: 298–309.

23.

Dawson

Merwick

Webb

, et al. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J 2021; 6: CLXXXVII–CXCI.

24.

Kleindorfer

Towfighi

Chaturvedi

, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association/American stroke association. Stroke 2021; 52: e364–e467.

25.

Aoki

Iguchi

Urabe

, et al. Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc 2019; 8: e012652.

26.

Japan Stroke Society Guideline 2021 for the Treatment of Stroke [Revised Version 2023] . Tokyo: Kyowa Kikaku Ltd, 2023.

27.

Okazaki

Tanaka

Yazawa

, et al. Optimal antithrombotics for ischemic stroke and concurrent atrial fibrillation and atherosclerosis: a randomized clinical trial. JAMA Neurol 2025; 82: 1227–1234.

28.

Fox

Piccini

Wojdyla

, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394.

29.

Hori

Matsumoto

Tanahashi

, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013; 77: 632–638.

30.

Bohula

Giugliano

Ruff

, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134: 24–36.

31.

Hijazi

Hohnloser

Oldgren

, et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J 2018; 198: 169–177.

32.

Hohnloser

Hijazi

Thomas

, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830.